P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

Bibliographic Details
Main Authors:	B. E. Wahlin, J. Brody, T. Phillips, R. Costello, P. Lugtenburg, R. Cordoba, L. Wang, J. Wu, B. Elliott, A. Abbas, J. Jørgensen
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847716.29326.a8

Similar Items

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
by: D. Belada, et al.
Published: (2022-06-01)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: R. Cordoba, et al.
Published: (2022-06-01)

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
by: M. R. Clausen, et al.
Published: (2022-06-01)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study
by: Hamdy Zawam, et al.
Published: (2018-06-01)

Metabolic pitfall of pseudoprogression after epcoritamab treatment
by: Osamu Imataki, et al.
Published: (2024-12-01)

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
by: L. H. Sehn, et al.
Published: (2022-06-01)

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma: a single-arm Meta analysis
by: Guo-Xin HUANG, et al.
Published: (2023-12-01)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
by: Andrew Ip, et al.
Published: (2023-08-01)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
by: Rumaisa Riaz, et al.
Published: (2023-07-01)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
by: Anna Sureda, et al.
Published: (2023-08-01)

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
by: Allison Rosenthal, et al.
Published: (2024-08-01)

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study
by: Guang‐Liang Chen, et al.
Published: (2024-08-01)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
by: P. Borchmann, et al.
Published: (2022-06-01)

James I of Aragon (1213–1276)
by: Marta Serrano-Coll
Published: (2021-11-01)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
by: LI Zhi-Ming, et al.
Published: (2023-08-01)

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China
by: Wei Guo, et al.
Published: (2022-06-01)

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report
by: CHEN Xiaojun, et al.
Published: (2022-01-01)

S313: HEALTH ECONOMIC EVALUATION OF THIRD-LINE INTERVENTIONS FOR TRANSPLANT-INELIGIBLE RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GERMANY
by: Melina Sophie Kurte, et al.
Published: (2023-08-01)

FRONT-LINE AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS: UNDERSTANDING THE REASONS FOR INELIGIBILITY AND ITS IMPACT IN SURVIVAL. REAL-WORLD PRACTICE IN A DEVELOPING COUNTRY
by: M.J. Atanazio, et al.
Published: (2020-11-01)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
by: Allison Rosenthal, et al.
Published: (2023-08-01)

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
by: Michael Roost Clausen, et al.
Published: (2023-08-01)

Isotopic effects in elastic and inelastic 12,13C + 16,18O scattering
by: A. T. Rudchik, et al.
Published: (2010-09-01)

Clinical characteristics and diagnoses of 1213 children referred to a first seizure clinic
by: Geertruida Slinger, et al.
Published: (2024-04-01)

P1695: REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING
by: Mahek Garg, et al.
Published: (2023-08-01)

De novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation.
by: Armstrong, R, et al.
Published: (2010)

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
by: Jun Cai, et al.
Published: (2020-12-01)

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation
by: Amalia Domingo-González, et al.
Published: (2024-09-01)

Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
by: Mohamed Elshebeiny, et al.
Published: (2016-09-01)

Trichodermin (4β-acetoxy-12,13-epoxytrichothec-9-ene)
by: Fu-Cheng Lin, et al.
Published: (2008-04-01)

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
by: Satoshi Yamasaki, et al.
Published: (2024-05-01)

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors
by: Seied Asadollah Mousavi, et al.
Published: (2018-07-01)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
by: Y. Xie, et al.
Published: (2022-06-01)

Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case
by: He-wei Zhang, et al.
Published: (2024-07-01)

Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
by: Pauline Gras, et al.
Published: (2012-04-01)

Adjuvant Gemcitabine-Oxaliplatin (GeMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
by: Bernard Paule, et al.
Published: (2009-01-01)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
by: Hilma J. van der Horst, et al.
Published: (2021-02-01)

P1610: IMPACT OF COVID-19 ON PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE COHORT STUDY
by: T. Silfverberg, et al.
Published: (2022-06-01)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
by: Aung M. Tun, et al.
Published: (2023-04-01)